People Who Go Off GLP-1s Are Experiencing a Sudden and Terrible Hunger

A University of Oxford review of 37 weight-loss medication studies covering over 9,000 participants found that stopping GLP-1 receptor agonists (e.g., Wegovy, Ozempic) led to weight regain four times faster than behavioral programs, with participants returning to baseline weight on average in 1.7 years and cardiometabolic markers reversing in about 1.4 years. The findings suggest benefits dissipate after cessation and underscore the need for long-term management strategies and wraparound support, with implications for sustained patient demand and prescribing practices in the obesity drug market.

Analysis

Market structure: GLP-1 cessation data implies chronic-use economics — manufacturers (Novo Nordisk NVO, Eli Lilly LLY) gain recurring-revenue optionality as patients likely resume or continue therapy, supporting 20–40% revenue tail through 2026 if coverage persists. Short-term winners also include CDMOs (Catalent CTLT, Lonza equivalents) as production scale must expand; losers include pure-play behavioral brands (WW) and elective bariatric providers facing demand shifts and pricing pressure. Supply/demand: expect tight supply windows next 3–12 months as ramped prescriptions meet finite peptide capacity, supporting premium pricing until new capacity online.

Risk assessment: Principal tail risks are payer pushback and regulatory limits on chronic coverage (Medicare/major insurers) within 3–24 months, or safety/label changes that trigger usage restrictions — either can halve revenue projections. Hidden dependencies: sustained demand relies on reimbursement policy, real-world adherence, and CDMO scale; if insurers mandate short-term courses with behavioral wraparound, addressable revenue could be cut >30%. Key catalysts: CMS/UK payer policy decisions and IQVIA prescription trends in next 30–90 days, and long-term cardiovascular outcomes data due 12–36 months.

Trade implications: Tactical trades favor 2–3% long NVO and 1–2% long LLY positions to capture durable pricing and volume upside, with stop-loss ~12% and time horizon 6–12 months. Pair trade: long LLY (1.5%) / short WW (WW) (0.5%) over 6–12 months; expect >15% relative outperformance if chronic-use thesis holds. Options: buy 9-month call spreads on LLY (buy ATM, sell 15–20% OTM) sized to 0.5% portfolio risk to capture upside while capping premium; close on payer-policy reversal.

Contrarian angles: Consensus underestimates payer resistance — if major insurers cap duration to <1 year, lifetime revenue growth could be cut by >40%, creating a buying opportunity only after price resets. Historical parallel: statins showed chronic-adoption but faced price regulation and guideline-driven use; GLP-1s risk similar politicized pricing in 12–36 months. Watch for a rise in compounding/black-market supply as an unintended consequence that could spur regulatory crackdowns and reputational risk for leaders.

Key Decisions for Investors

• Establish a 2–3% long position in Novo Nordisk (NVO) with a 6–12 month horizon; target +20–40% upside if prescription growth continues, set stop-loss at -12% and trim if CMS or a top-3 US insurer issues coverage caps within 90 days.
• Initiate a relative-value pair: long Eli Lilly (LLY) 1.5% / short WW International (WW) 0.5% sized to net 1% portfolio exposure; expected 6–12 month alpha >15% if chronic-use adoption sustains and behavioral incumbents underperform.
• Buy 9-month call spreads on LLY (buy near-the-money, sell 15–20% OTM) sized to 0.5% portfolio downside risk to capture continued demand; close or roll on first major payer policy announcement or on >15% move in underlying.
• Establish a 0.5–1% exposure to CDMO exposure (Catalent CTLT) to capture manufacturing tailwinds; exit/triple-check if quarterly order backlog fails to grow by >=20% QoQ or if new capacity announcements show >12-month lead times.